Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

2 treatments under study, led by Bexsero Vaccine 2 Doses 1 Month Apart

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 5/100

Termination Rate

0.0%

0 terminated out of 2 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

50%

1 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed with results

Key Signals

1 with results100% success

Data Visualizations

Phase Distribution

1Total
Phase 3 (1)

Trial Status

Recruiting1
Completed1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (2)

Showing 2 of 2 trials
NCT07379151RecruitingPrimary

Evaluation of the Antibody Persistence Beyond Five Years After Immunization With MenFiveTM (NmCV-5), a Pentavalent Meningococcal ACYWX Conjugate Vaccine

NCT01894919Phase 3CompletedPrimary

Antibody Persistence, and Safety and Tolerability of a Booster Dose of the Meningococcal B Vaccine After the Completion of the Vaccination Course in Study V72_28

Showing all 2 trials

Research Network

Common Treatments

  • Bexsero Vaccine 2 Doses 1 Month Apart1
  • Bexsero Vaccine 1 Dose At Study Month Zero1

Active Sponsors

  • Novartis Vaccines1
  • GSK1
  • Serum Institute of India Pvt. Ltd.1

Top Investigators

Related Conditions

  • Meningococcal Meningitis1

Activity Timeline